PDE4A and chronic obstructive pulmonary disease: Inhibiting PDE4, and, thus, increasing cAMP, reduces the recruitment of inflammatory leukocytes to tissues and has already been used to treat inflammatory diseases such as chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and neuroinflammation [67,68].